467 related articles for article (PubMed ID: 24857147)
1. Mass spectrometry-based proteomics: from cancer biology to protein biomarkers, drug targets, and clinical applications.
Jimenez CR; Verheul HM
Am Soc Clin Oncol Educ Book; 2014; ():e504-10. PubMed ID: 24857147
[TBL] [Abstract][Full Text] [Related]
2. Strategies in functional proteomics: Unveiling the pathways to precision oncology.
Favicchio R; Thepaut C; Zhang H; Arends R; Stebbing J; Giamas G
Cancer Lett; 2016 Nov; 382(1):86-94. PubMed ID: 26850375
[TBL] [Abstract][Full Text] [Related]
3. Proteomic Approaches for Biomarker Panels in Cancer.
Tanase C; Albulescu R; Neagu M
J Immunoassay Immunochem; 2016; 37(1):1-15. PubMed ID: 26565430
[TBL] [Abstract][Full Text] [Related]
4. Clinical proteomics in cancer: Where we are.
Panis C; Pizzatti L; Souza GF; Abdelhay E
Cancer Lett; 2016 Nov; 382(2):231-239. PubMed ID: 27561426
[TBL] [Abstract][Full Text] [Related]
5. Emerging Affinity-Based Proteomic Technologies for Large-Scale Plasma Profiling in Cardiovascular Disease.
Smith JG; Gerszten RE
Circulation; 2017 Apr; 135(17):1651-1664. PubMed ID: 28438806
[TBL] [Abstract][Full Text] [Related]
6. Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer.
Murray HC; Dun MD; Verrills NM
Expert Opin Drug Discov; 2017 May; 12(5):431-447. PubMed ID: 28286965
[TBL] [Abstract][Full Text] [Related]
7. Cancer proteomics: developments in technology, clinical use and commercialization.
Yeat NC; Lin C; Sager M; Lin J
Expert Rev Proteomics; 2015 Aug; 12(4):391-405. PubMed ID: 26145529
[TBL] [Abstract][Full Text] [Related]
8. Oncoproteomics: Trials and tribulations.
Zhou L; Li Q; Wang J; Huang C; Nice EC
Proteomics Clin Appl; 2016 Apr; 10(4):516-31. PubMed ID: 26518147
[TBL] [Abstract][Full Text] [Related]
9. Introduction: Cancer Gene Networks.
Clarke R
Methods Mol Biol; 2017; 1513():1-9. PubMed ID: 27807826
[TBL] [Abstract][Full Text] [Related]
10. Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity.
Wang J; Mouradov D; Wang X; Jorissen RN; Chambers MC; Zimmerman LJ; Vasaikar S; Love CG; Li S; Lowes K; Leuchowius KJ; Jousset H; Weinstock J; Yau C; Mariadason J; Shi Z; Ban Y; Chen X; Coffey RJC; Slebos RJC; Burgess AW; Liebler DC; Zhang B; Sieber OM
Gastroenterology; 2017 Oct; 153(4):1082-1095. PubMed ID: 28625833
[TBL] [Abstract][Full Text] [Related]
11. High-throughput proteomics and AI for cancer biomarker discovery.
Xiao Q; Zhang F; Xu L; Yue L; Kon OL; Zhu Y; Guo T
Adv Drug Deliv Rev; 2021 Sep; 176():113844. PubMed ID: 34182017
[TBL] [Abstract][Full Text] [Related]
12. Emerging applications for phospho-proteomics in cancer molecular therapeutics.
Moran MF; Tong J; Taylor P; Ewing RM
Biochim Biophys Acta; 2006 Dec; 1766(2):230-41. PubMed ID: 16889898
[TBL] [Abstract][Full Text] [Related]
13. Quantitative Proteomic Analysis of Differentially Expressed Protein Profiles Involved in Pancreatic Ductal Adenocarcinoma.
Kuo KK; Kuo CJ; Chiu CY; Liang SS; Huang CH; Chi SW; Tsai KB; Chen CY; Hsi E; Cheng KH; Chiou SH
Pancreas; 2016 Jan; 45(1):71-83. PubMed ID: 26262590
[TBL] [Abstract][Full Text] [Related]
14. Cancer biomarker discovery and translation: proteomics and beyond.
Hristova VA; Chan DW
Expert Rev Proteomics; 2019 Feb; 16(2):93-103. PubMed ID: 30556752
[TBL] [Abstract][Full Text] [Related]
15. High-throughput and targeted in-depth mass spectrometry-based approaches for biofluid profiling and biomarker discovery.
Jimenez CR; Piersma S; Pham TV
Biomark Med; 2007 Dec; 1(4):541-65. PubMed ID: 20477373
[TBL] [Abstract][Full Text] [Related]
16. Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery.
Matta A; Ralhan R; DeSouza LV; Siu KW
Mass Spectrom Rev; 2010; 29(6):945-61. PubMed ID: 20945361
[TBL] [Abstract][Full Text] [Related]
17. Mass spectrometry based translational proteomics for biomarker discovery and application in colorectal cancer.
Ma H; Chen G; Guo M
Proteomics Clin Appl; 2016 Apr; 10(4):503-15. PubMed ID: 26616366
[TBL] [Abstract][Full Text] [Related]
18. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
19. Proteomics in cancer screening and management in gynecologic cancer.
Hu W; Wu W; Kobayashi R; Kavanagh JJ
Curr Oncol Rep; 2004 Nov; 6(6):456-62. PubMed ID: 15485615
[TBL] [Abstract][Full Text] [Related]
20. Investigation of cancer drug resistance mechanisms by phosphoproteomics.
Boulos JC; Yousof Idres MR; Efferth T
Pharmacol Res; 2020 Oct; 160():105091. PubMed ID: 32712320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
